BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 26896819)

  • 1. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
    Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
    Elife; 2018 Sep; 7():. PubMed ID: 30226468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
    Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
    J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
    J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
    Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
    BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
    Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
    J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
    Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
    Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.
    Haupt J; Deichsel A; Stange K; Ast C; Bocciardi R; Ravazzolo R; Di Rocco M; Ferrari P; Landi A; Kaplan FS; Shore EM; Reissner C; Seemann P
    Hum Mol Genet; 2014 Oct; 23(20):5364-77. PubMed ID: 24852373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
    Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
    J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
    Wentworth KL; Masharani U; Hsiao EC
    Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV-Mediated Targeting of the Activin A-ACVR1
    Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
    Towler OW; Shore EM; Kaplan FS
    Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.